HealthPartners Faces Wrongful Death Lawsuit over Use of Remdesivir for COVID

Regions Hospital

Two Minnesotans have filed a wrongful death lawsuit against HealthPartners, Regions Hospital, and affiliated healthcare workers relating to the hospital’s protocols for treating COVID-19. The lawsuit claims that these protocols caused the deaths of two patients.

Specifically, the civil suit alleges that the plaintiffs’ spouses “were given Remdesivir against their wishes as part of a protocol which actually harmed them; and which protocol has served to financially enrich Health Partners, Inc., and Regions Hospital.”

Read More

Drugmaker’s Study Shows Remdesivir Reduces COVID-19 Hospitalizations

Gilead Sciences announced in a press release Wednesday that its COVID-19 drug remdesivir reduces hospitalizations by 87% in high-risk patients.

The study consisted of 562 patients who were randomly given either remdesivir to a placebo. The company said that it saw an 87% reduction in hospitalizations after day 28, according to the press release. The trial was supposed to have over 1,000 subjects but the Gilead halted enrollment after other COVID-19 drugs became readily available.

Read More

WHO Study Finds Remdesivir Didn’t Help COVID-19 Patients

A large study led by the World Health Organization suggests that the antiviral drug remdesivir did not help hospitalized COVID-19 patients, in contrast to an earlier study that made the medicine a standard of care in the United States and many other countries.

The results announced Friday do not negate the previous ones, and the WHO study was not as rigorous as the earlier one led by the U.S. National Institutes of Health. But they add to concerns about how much value the pricey drug gives because none of the studies have found it can improve survival.

Read More

‘An Amazing Deal’: U.S. Secures Most of Global Remdesivir Supply

The United States has secured nearly the entire global supply of remdesivir, a drug that has been effective in fighting coronavirus.

Remdesivir, which is manufactured by American pharmaceutical giant Gilead, has proven to help patients with coronavirus recover faster, according to The Guardian. The U.S. Department of Health and Human Services (HHS) secured more than 500,000 doses of the drug, accounting for the vast majority of Gilead’s July, August and September supply, according to a Monday press release.

Read More

Money and Politics Behind Anti-Hydroxychloroquine Bias, New Report Suggests

Remdesivir, an antiviral medication that was developed by the biopharmaceutical company Gilead Sciences, has been widely touted as the most promising drug to treat COVID-19, even though – so far – the new and expensive drug does not seem to be terribly effective at fighting the disease.

The anti-malaria drug hydroxychloroquine, on the other hand, is cheap, has been used safely for decades, and has shown great promise as a weapon in the fight against the coronavirus – yet after President Trump mentioned it as a promising potential treatment for the disease, the media immediately blasted him for touting an “unproven” and potentially unsafe drug.

Read More